The Supreme Court of India has directed the Union government to form an expert committee within two weeks to address unethical pharmaceutical marketing. The panel must recommend whether the industry needs a legally enforceable statutory framework to replace voluntary codes. The directive follows petitions highlighting how corporate freebies, such as AbbVie's ₹1.91 crore luxury trips and Micro Labs' ₹1,000 crore in marketing incentives, lead to drug over-prescription and higher patient costs. The court scheduled a compliance hearing for January 29, 2027.
Supreme Court directive on expert committee
- ▪The Supreme Court of India ordered the expert committee to submit its recommendations to the Centre within two months of its first meeting and scheduled a compliance hearing for January 29, 2027.
- ▪The Supreme Court of India directed the Union government on October 8, 2026 to constitute an expert committee within two weeks to examine unethical pharmaceutical marketing practices.
- ▪The expert committee is tasked with recommending whether the pharmaceutical industry needs a legally enforceable statutory framework to regulate marketing practices instead of the existing voluntary framework.
FMRAI petition to the Supreme Court
- ▪The Federation of Medical and Sales Representatives Associations of India petitioned the court to curb unethical marketing practices, including pharmaceutical companies offering expensive gifts, foreign trips, cash grants, and other freebies to doctors.
- ▪The Supreme Court of India issued its directive under Articles 32 and 142 of the Constitution of India in response to a public interest litigation filed by the Federation of Medical and Sales Representatives Associations of India.
Influence of marketing on prescribing decisions
- ▪The Federation of Medical and Sales Representatives Associations of India argued that aggressive sales promotions influence doctors to over-prescribe drugs, resulting in higher costs and serious public health risks for patients.
- ▪The Supreme Court of India noted that commercial incentives offered to doctors to promote medicines can influence prescribing decisions, potentially leading to unnecessary, irrational, or expensive prescriptions.
Debate on statutory framework for pharmaceutical marketing
- ▪The Supreme Court of India emphasized that the regulatory framework must balance the legitimate interests of the pharmaceutical industry against the paramount consideration of protecting patients and public health.
- ▪The Union government previously explored giving statutory backing to pharmaceutical marketing under the Essential Commodities Act, 1955 and the Drugs and Cosmetics Act, 1940, but faced jurisdictional and implementation challenges.
- ▪Petitioners argued that the existing Uniform Code for Pharmaceutical Marketing Practices, including the updated 2024 version, lacks an adequate statutory enforcement mechanism to hold pharmaceutical companies accountable.
- ▪Solicitor General Tushar Mehta stated that the existing framework primarily regulates the conduct of medical practitioners, whereas a separate mechanism is required to proceed directly against pharmaceutical companies.
- ▪A high-level committee headed by Dr. V.K. Paul in September 2022 concluded that the Uniform Code for Pharmaceutical Marketing Practices did not immediately need statutory force, recommending instead a strengthened voluntary framework.
AbbVie Healthcare sponsorship case
- ▪In August 2026, the Delhi High Court stayed disciplinary proceedings against the healthcare professionals involved in the AbbVie Healthcare India Pvt. Ltd sponsorship case because the action stemmed from an anonymous complaint.
- ▪In 2024, a government probe found that AbbVie Healthcare India Pvt. Ltd spent approximately ₹1.91 crore to sponsor luxury foreign trips to Monaco and Paris for 30 doctors, leading to a reprimand and tax liability evaluations.
CCTV surveillance at medical stores
- ▪The Union health ministry proposed mandatory CCTV surveillance at medical stores selling Schedule H, H1, and X prescription drugs to curb drug abuse, requiring recordings to be maintained for three months.
- ▪The Union health ministry first proposed the CCTV surveillance measure for medical stores in 2021 to prevent drug abuse by children.
Debatable claims
- ▪Commercial incentives from drug companies compromise the integrity of doctors' prescribing decisions
- ▪Aggressive pharmaceutical marketing is a primary driver of high medicine costs for patients
- ▪The Supreme Court of India oversteps its authority by directing executive action on pharmaceutical marketing
- ▪A voluntary code is insufficient to regulate pharmaceutical marketing practices in India
Story comments
Loading comments…